Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing.

Abstract

Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in "real-world" populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.

• Authors: Shelsey W Johnson, Lauren Finlay, Stephen C Mathai, Ronald H Goldstein, Bradley A Maron
• Journal: Pulmonary circulation (Pulm Circ) Vol. 12 Issue 3 Pg. e12126 (Jul 2022) ISSN: 2045-8932 [Print] United States
• PMID: 36092795 (Publication Type: Journal Article)
• Copyright: © 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.